Sanofi India Ltd
Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]
- Market Cap ₹ 9,132 Cr.
- Current Price ₹ 3,965
- High / Low ₹ 6,718 / 3,951
- Stock P/E 26.4
- Book Value ₹ 326
- Dividend Yield 2.95 %
- ROCE 57.5 %
- ROE 43.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 47.8%
- Company has been maintaining a healthy dividend payout of 71.8%
Cons
- Stock is trading at 12.2 times its book value
- The company has delivered a poor sales growth of -8.74% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,977 | 2,193 | 2,367 | 2,460 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 2,851 | 2,013 | 1,837 | |
| 1,639 | 1,817 | 1,832 | 1,921 | 2,146 | 2,403 | 2,186 | 2,194 | 2,066 | 2,047 | 1,522 | 1,346 | |
| Operating Profit | 339 | 376 | 535 | 538 | 625 | 667 | 716 | 762 | 704 | 804 | 491 | 491 |
| OPM % | 17% | 17% | 23% | 22% | 23% | 22% | 25% | 26% | 25% | 28% | 24% | 27% |
| 131 | 218 | 66 | 79 | 88 | 33 | 45 | 564 | 204 | 83 | 79 | -8 | |
| Interest | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 97 | 113 | 119 | 102 | 103 | 100 | 82 | 67 | 42 | 40 | 37 | 37 |
| Profit before tax | 373 | 481 | 480 | 515 | 610 | 600 | 677 | 1,258 | 864 | 846 | 531 | 445 |
| Tax % | 29% | 33% | 37% | 37% | 38% | 31% | 29% | 25% | 28% | 29% | 22% | 27% |
| 264 | 322 | 304 | 326 | 381 | 414 | 478 | 944 | 621 | 603 | 414 | 327 | |
| EPS in Rs | 114.61 | 139.78 | 132.26 | 141.74 | 165.48 | 180.09 | 207.65 | 410.61 | 269.83 | 262.26 | 179.78 | 142.04 |
| Dividend Payout % | 39% | 46% | 51% | 50% | 51% | 194% | 176% | 119% | 211% | 64% | 65% | 87% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -9% |
| 3 Years: | -13% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -7% |
| 3 Years: | -13% |
| TTM: | -22% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -5% |
| 3 Years: | 4% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 37% |
| 3 Years: | 48% |
| Last Year: | 43% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
| Reserves | 1,463 | 1,604 | 1,860 | 2,003 | 2,196 | 2,419 | 2,096 | 2,203 | 1,253 | 992 | 838 | 726 |
| 0 | 0 | 0 | 0 | 0 | 0 | 23 | 25 | 24 | 19 | 19 | 18 | |
| 742 | 778 | 658 | 751 | 765 | 802 | 777 | 811 | 772 | 681 | 732 | 488 | |
| Total Liabilities | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,255 |
| 648 | 877 | 817 | 769 | 733 | 499 | 464 | 334 | 306 | 315 | 312 | 304 | |
| CWIP | 210 | 22 | 34 | 30 | 21 | 17 | 10 | 13 | 24 | 16 | 18 | 12 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| 1,369 | 1,505 | 1,690 | 1,978 | 2,230 | 2,728 | 2,444 | 2,714 | 1,743 | 1,382 | 1,281 | 939 | |
| Total Assets | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,255 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 265 | 213 | 322 | 435 | 374 | 412 | 611 | 559 | 399 | 231 | 462 | 438 | |
| 61 | 36 | -155 | -79 | -73 | 66 | 276 | 631 | 651 | 36 | -178 | -11 | |
| -122 | -147 | -180 | -188 | -197 | -183 | -810 | -849 | -1,583 | -878 | -392 | -448 | |
| Net Cash Flow | 205 | 102 | -13 | 168 | 104 | 295 | 78 | 341 | -533 | -612 | -109 | -21 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 21 | 24 | 22 | 29 | 21 | 27 | 19 | 18 | 17 | 17 | 42 | 35 |
| Inventory Days | 179 | 173 | 169 | 151 | 154 | 127 | 107 | 110 | 125 | 202 | 186 | 127 |
| Days Payable | 122 | 81 | 79 | 119 | 110 | 100 | 93 | 105 | 109 | 89 | 151 | 79 |
| Cash Conversion Cycle | 78 | 115 | 112 | 61 | 65 | 54 | 33 | 22 | 33 | 130 | 77 | 83 |
| Working Capital Days | 26 | 9 | 79 | 17 | 18 | 35 | -8 | -20 | -19 | 24 | 20 | 7 |
| ROCE % | 22% | 26% | 27% | 26% | 29% | 28% | 32% | 35% | 41% | 71% | 49% | 58% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
3h - Video of investors/analysts call (26 Feb 2026) on FY 2025 results uploaded on company website.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
1d - Annual Secretarial Compliance Report for year ended 31 Dec 2025 by Parikh & Associates.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Copies of the Newspaper Publication of Financial Results for the quarter and year ended 31st December, 2025 of the Company published on 26th February 2026, …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
1d - Will be made at the investor call.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
2d - Approved FY2025 audited results; final dividend Rs48/share (total Rs123); appointed Kesari and Chakraborty; Hrosz resigned.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Nov 2023TranscriptPPT
-
May 2023TranscriptPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Mar 2021TranscriptAI SummaryPPT
Parent Company[1]
Sanofi Global and its 100% subsidiary - Hoechst GmbH, are the shareholders of Sanofi India and together hold 60.40%. Company's follows parent company's financial year hence, Financial year is same as Calender Year.